Clinical trial · Observational
Expressiona and Diagnostic Potential of miRNAs in NSCLC
The Expression Profiling of Serum miRNAs (106b-5p, 601, and 760) in Non-small Cell Lung Cancer Patients
NCT05815407CI-TRIAL-00065695completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Its to explore the expression pattern, diagnostic and prognostic potentials of miRs (106b-5p, 601 and 760) in serum of NSCLC patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- NSCLC patients
- description
- Patients were diagnosed with NSCLC at any stage, then will be subdivided into Early stage, Lympho-node involvement stage and Distant metastatic stage
- interventionNames
- Other: No intervention
- label
- Control subjects
- description
- Appearantly healthy age-matched individuals
- interventionNames
- Other: No intervention
Primary outcomes (1)
- measure
- Determination of the expression
- timeFrame
- By the end of the study (September 2022)
- description
- Expression profiling of the selected miRNAs
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * First time and recently diagnosed NSCLC patient Exclusion Criteria: * Recurrent NSCLC * Start of chemotherapy, radiotherapy or surgical intervention * Previous treatment * Cancer history
References
Publications (0)
Data not yet available
No reference posted for this study.